Reviva Pharmaceuticals Holdings, INC.: insider trades · United States · SEC (Form 4)

About Reviva Pharmaceuticals Holdings, INC.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is a U.S.-based clinical-stage biopharmaceutical company headquartered in Cupertino, California, United States. For French-speaking investors, it fits the profile of a small-cap healthcare name whose equity story is driven less by current sales than by the progress of a proprietary drug pipeline, clinical data, regulatory milestones, and financing capacity. The company was originally incorporated in Delaware in 2006 and has since developed an internal chemical genomics and medicinal chemistry platform. It also reports a foreign operating subsidiary, Reviva Pharmaceuticals India Pvt. Ltd., which gives it a modest international operating footprint beyond the United States. Reviva’s business model is centered on discovering, developing, and seeking to commercialize next-generation therapeutics for diseases with significant unmet medical need, especially in central nervous system, inflammatory, cardiometabolic, and related therapeutic areas. Its pipeline is currently anchored by two drug candidates: brilaroxazine (RP5063) and RP1208. Brilaroxazine is the lead and most strategically important asset. The company has positioned it primarily for schizophrenia and more broadly for neuropsychiatric disorders, while also describing potential applications across other CNS and inflammatory settings. RP1208 remains part of the portfolio, but the investment case is overwhelmingly dependent on the progression of brilaroxazine through late-stage development, regulatory engagement, and, eventually, a possible partnership or commercialization path. From a competitive standpoint, Reviva is not yet a commercial-stage pharmaceutical company and does not compete on revenue scale, geographic reach, or product breadth with large-cap peers. Instead, it competes in the high-risk, high-upside category of clinical biotech, where valuation is shaped by data quality, trial design, patent protection, and the market’s perception of probability-adjusted success. That makes the stock especially sensitive to clinical readouts, FDA interactions, and capital raises. Recent corporate developments are material. Reviva reported several equity financings in 2025 and March 2026 to support research and development, including funding for its planned RECOVER-2 Phase 3 trial in schizophrenia. Following the March 2026 financing, the company said it had approximately $23 million in cash and cash equivalents and expected to fund operations into Q1 2027. Reviva also completed a 1-for-20 reverse stock split effective March 9, 2026, a common action among micro- and small-cap biotechnology issuers seeking to maintain listing compliance and improve share-price optics. On the pipeline side, management indicated it plans to initiate RECOVER-2 in mid-2026 and continue pursuing partnerships. In addition, the European Patent Office granted a patent in November 2025 covering brilaroxazine for pulmonary fibrosis, including idiopathic pulmonary fibrosis, which strengthens the company’s intellectual-property position in key global markets. Overall, RVPH remains a speculative NASDAQ-listed U.S. biotech story with limited current commercialization but meaningful optionality if late-stage clinical execution improves.